Monocentric evaluation of the skin and cardiac toxicities of the concomitant administration of trastuzumab and radiotherapy;Évaluation monocentrique de la tolérance de l'association concomitante de trastuzumab et de radiothérapie

Cancer/Radiotherapie

Volumn 13, Issue 4, 2009, Pages 276-280

  Kirova, Y M ^a   Caussa, L ^a   Granger, B ^a   Savignoni, A ^a   Dendale, R ^a   Campana, F ^a   Tournat, H ^a   Pierga, J Y ^a   Fourquet, A ^a   Bollet, M A ^a  

^a INSTITUT CURIE   (France)

Author keywords

Breast cancer; Radiotherapy; Toxicity; Trastuzumab

Indexed keywords

ANTHRACYCLINE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CARDIOLOGIST; CARDIOTOXICITY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; EVALUATION RESEARCH; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRRADIATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT DURATION; BREAST TUMOR; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIOTHERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HUMANS; LYMPHATIC IRRADIATION; MIDDLE AGED; PROSPECTIVE STUDIES; RADIODERMATITIS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 67649401702     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2009.02.008     Document Type: Article

References (25)

1. Alm En-Din M.A., Bellon J.R., Strom E.A., Bourgier C., Jagsi R., Niemierko A., et al. Radiation treatments may contribute to the development of cardiac dysfunction in breast cancer patients treated with chemotherapy and trastuzumab. Int J Radiat Oncol Biol Phys 72 (2008) S89-S90
2. Belkacemi Y., Gligorov J., Ozsahin M., Marsiglia H., De Lafontan B., Laharie-Mineur H., et al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: Acute toxicity analyses from the French multicentric study. Ann Oncol 19 (2008) 1110-1116
3. Belkacemi Y., Laharie-Mineur H., Gligorov J., and Azria D. Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer. Cancer Radiother 11 (2007) 266-275
4. Bellon J.R., Gover M.T., Burstein H.J., Harris J.R., and Harris L.N. Concurrent Trastuzumab and radiation therapy (RT) in the adjuvant treatment of breast cancer. Int J Radiat Oncol Biol Phys 63 (2005) S55-S56
5. Bollet M.A., Campana F., Kirova Y.M., Dendale R., Saliou M.G., Rosenwald J.C., et al. Breast radiotherapy in women with pectus excavatum (funnel chest): Is the lateral decubitus technique an answer? A dosimetric study. Br J Radiol 79 (2006) 785-790
6. Campana F., Kirova Y.M., Rosenwald J.C., Dendale R., Vilcoq J.R., Dreyfus H., et al. Breast radiotherapy in the lateral decubitus position: A technique to prevent lung and heart irradiation. Int J Radiat Oncol Biol Phys 61 (2005) 1348-1354
7. Castro Pena P, Kirova Y, Campana F, Dendale R, Bollet MA, Fournier-Bidoz N, et al. Anatomical, Clinical and radiological delineation of target volumes in breast cancer radiotherapy planning: individual variability, questions and answers. Br J Radiol 2009:doi:10.1259/bjr/96865511.
8. Chargari C, Fromantin I, Kirova Y. Intérêt des applications cutanées en cours de radiothérapie pour la prévention et le traitement des épithélites radio-induites. Cancer Radiother 2009:doi:10.1016/j.canrad.2009.04.003.
9. Couturier J., Vincent-Salomon A., Mathieu M.C., Valent A., and Bernheim A. Diagnosis of HER2 gene amplification in breast carcinoma. Pathol Biol (Paris) 56 (2008) 375-379
10. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
11. Ewer M.S., Vooletich M.T., Durand J.B., Woods M.L., Davis J.R., Valero V., et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 23 (2005) 7820-7826
12. Halyard M.Y., Pisansky T.M., Solin L.J., Marks L.B., Pierce L.J., Dueck A., et al. Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831. J Clin Oncol (Meeting Abstracts) 24 (2006) 523
13. Hennequin C., Romestaing P., and Maylin C. Irradiation of lymph nodes areas in breast cancer. Cancer Radiother 12 (2008) 559-564
14. Hurkmans C.W., Borger J.H., Bos L.J., van der Horst A., Pieters B.R., Lebesque J.V., et al. Cardiac and lung complication probabilities after breast cancer irradiation. Radiother Oncol 55 (2000) 145-151
15. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., Alanko T., Kataja V., Asola R., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 (2006) 809-820
16. Kirova Y.M., Campana F., Fournier-Bidoz N., Stilhart A., Dendale R., Bollet M.A., et al. Postmastectomy electron beam chest wall irradiation in women with breast cancer: A clinical step toward conformal electron therapy. Int J Radiat Oncol Biol Phys 69 4 (2007) 1139-1144
17. Kirova Y.M., Fournier-Bidoz N., Servois V., Laki F., Pollet G.A., Salmon R., et al. How to boost the breast tumor bed? A Multidisciplinary Approach in eight steps. Int J Radiat Oncol Biol Phys 72 (2008) 494-500
18. Kirova Y.M., Servois V., Campana F., Dendale R., Bollet M.A., Laki F., et al. CT-scan based localization of the internal mammary chain and supra clavicular nodes for breast cancer radiation therapy planning. Radiother Oncol 79 (2006) 310-315
19. Kong F.M., Klein E.E., Bradley J.D., Mansur D.B., Taylor M.E., Perez C.A., et al. The impact of central lung distance, maximal heart distance, and radiation technique on the volumetric dose of the lung and heart for intact breast radiation. Int J Radiat Oncol Biol Phys 54 (2002) 963-971
20. Musat E., Poortmans P., Van den Bogaert W., Struikmans H., Fourquet A., Bartelink H., et al. Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes. Eur J Cancer 43 (2007) 718-724
21. Pietras R.J., Poen J.C., Gallardo D., Wongvipat P.N., Lee H.J., and Slamon D.J. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59 (1999) 1347-1355
22. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
23. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
24. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
25. Smith I., Procter M., Gelber R.D., Guillaume S., Feyereislova A., Dowsett M., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369 (2007) 29-36